EZH2 Inhibition Suppresses Bladder Cancer Cell Growth and Metastasis Via the JAK2/STAT3 Signaling Pathway

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jul 11

PMID 31289569

Citations 23

Authors

Zhiyuan Chen

Yang Du

Xiuheng Liu

Hui Chen

Xiaodong Weng

Jia Guo

Min Wang

Xiao Wang

Lei Wang

Affiliations

Soon will be listed here.

Abstract

The aim of the current study was to investigate the role of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) in the progression of bladder cancer. Human bladder cancer tissue samples were analyzed by immunohistochemistry, and the association between the clinicopathological parameters and EZH2 expression was analyzed. The proliferation, apoptosis and migration ability of the human bladder cancer cell lines E-J and 5637 with or without the EZH2 inhibitor UNC1999 was investigated. The effect of UNC1999 was further explored in a xenograft model of nude mice. The and expression levels of EZH2, janus kinase 2, signal transducer and activator of transcription 3 and their phosphorylated forms were examined by western blotting. The expression levels of EZH2, JAK2 and STAT3 were increased in bladder cancer tissue compared with normal adjacent tissue. Furthermore, the expression of EZH2 was increased in tumors with a higher TNM Classification of Malignant Tumors stage and histological grade compared with tumors with a lower stage and grade. The human bladder cancer cell lines E-J and 5637 treated with UNC1999 demonstrated reduced cell proliferation, apoptosis and migration compared with cells treated without UNC1999. Additionally, EZH2 may promote the proliferation and migration of bladder cancer via the JAK2/STAT3 pathway. EZH2 may serve an important role in the proliferation and migration of human bladder cancer cells, and may aid in the development of novel treatment strategies for bladder cancer.

Citing Articles

Regulation of histone H3K27 methylation in inflammation and cancer.

Ma J, Zhang Y, Li J, Dang Y, Hu D Mol Biomed. 2025; 6(1):14.

PMID: 40042761 PMC: 11882493. DOI: 10.1186/s43556-025-00254-x.

Treating human cancer by targeting EZH2.

Xu M, Xu C, Wang R, Tang Q, Zhou Q, Wu W Genes Dis. 2025; 12(3):101313.

PMID: 40028035 PMC: 11870178. DOI: 10.1016/j.gendis.2024.101313.

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.

Hsu C, Mohammed A, Hjazi A, Uthirapathy S, Renuka J, Singh A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960560 DOI: 10.1007/s00210-025-03883-9.

Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.

Tsamouri M, Kent M, Mudryj M, Ghosh P Vet Oncol. 2025; 1.

PMID: 39944718 PMC: 11815638. DOI: 10.1186/s44356-024-00011-2.

Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review.

Wang M, Sussman J, Xu J, Patel R, Elghawy O, Rawla P Life (Basel). 2025; 14(12.

PMID: 39768352 PMC: 11678550. DOI: 10.3390/life14121645.

References

Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

Muller J, Hart C, Francis N, Vargas M, Sengupta A, Wild B . Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111(2):197-208. DOI: 10.1016/s0092-8674(02)00976-5. View

Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F . Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20. PMC: 1223585. DOI: 10.1042/BJ20030407. View

Pasini D, Bracken A, Hansen J, Capillo M, Helin K . The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol. 2007; 27(10):3769-79. PMC: 1899991. DOI: 10.1128/MCB.01432-06. View

Chamberlain S, Yee D, Magnuson T . Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells. 2008; 26(6):1496-505. PMC: 2630378. DOI: 10.1634/stemcells.2008-0102. View

Gonzalez M, Li X, Toy K, DuPrie M, Ventura A, Banerjee M . Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2008; 28(6):843-53. PMC: 2643353. DOI: 10.1038/onc.2008.433. View

Devarajan E, Huang S . STAT3 as a central regulator of tumor metastases. Curr Mol Med. 2009; 9(5):626-33. DOI: 10.2174/156652409788488720. View

10.

Karanikolas B, Figueiredo M, Wu L . Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res. 2009; 7(9):1456-65. PMC: 2794652. DOI: 10.1158/1541-7786.MCR-09-0121. View

11.

Yan K, Zhang C, Feng J, Hou L, Yan L, Zhou Z . Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol. 2011; 661(1-3):1-7. DOI: 10.1016/j.ejphar.2011.04.021. View

12.

Wagner K, Schmidt J . The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog. 2012; 10:32. PMC: 3262999. DOI: 10.4103/1477-3163.90677. View

13.

Racioppi M, DAgostino D, Totaro A, Pinto F, Sacco E, DAddessi A . Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int. 2012; 88(3):249-58. DOI: 10.1159/000335556. View

14.

Kim M, Nam H, Kim H, Han S, Im S, Kim T . OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013; 335(1):145-52. DOI: 10.1016/j.canlet.2013.02.010. View

15.

Hammerle M, Gutschner T, Uckelmann H, Ozgur S, Fiskin E, Gross M . Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology. 2013; 58(5):1703-12. DOI: 10.1002/hep.26537. View

16.

Shen H, Morrison C, Zhang J, Underwood 3rd W, Yang N, Frangou C . 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013; 4(11):2124-34. PMC: 3875774. DOI: 10.18632/oncotarget.1485. View

17.

Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W . The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013; 4(12):2532-49. PMC: 3926847. DOI: 10.18632/oncotarget.1503. View

18.

Sun J, Yu M, Lu Y, Thakur C, Chen B, Qiu P . Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation. Cancer Lett. 2014; 346(2):257-63. PMC: 3976992. DOI: 10.1016/j.canlet.2014.01.002. View

19.

Reijm E, Timmermans A, Look M, Meijer-van Gelder M, Stobbe C, van Deurzen C . High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014; 25(11):2185-2190. DOI: 10.1093/annonc/mdu391. View

20.

Xu B, On D, Ma A, Parton T, Konze K, Pattenden S . Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2014; 125(2):346-57. PMC: 4287641. DOI: 10.1182/blood-2014-06-581082. View